The device is designed for small blood samples collected through minimally invasive methods, including finger pricks. Once a sample is placed inside the testing unit, integrated sensors measure properties of the blood. Those measurements are processed by computational models that generate results and transmit them digitally to patients and healthcare professionals. By moving part of the testing process closer to the patient, the system could eventually support more frequent monitoring in homes, clinics and other community settings.

Traditional blood testing usually produces a snapshot of physiology at a particular moment. That snapshot can be clinically valuable, but it may not reveal subtle changes that emerge between appointments. Algocyte’s approach is intended to build a time series from repeated measurements. Artificial intelligence can compare new results with an individual’s previous readings, potentially helping identify gradual shifts in blood-cell levels or other physiological signals before they become obvious through symptoms or a single conventional test.

This capability could be especially important for people receiving treatments that require regular surveillance. Patients undergoing chemotherapy, for example, may need repeated blood tests to assess how treatment is affecting their blood cells and whether their immune system is being compromised. Similar monitoring is required for people taking medicines such as clozapine, which can cause serious changes in white blood cell counts in a small proportion of patients. A convenient testing system could reduce the burden of repeated hospital visits while allowing clinicians to maintain closer oversight.

The technology combines several technical disciplines. Bioengineering is used to create a compact platform capable of handling a blood sample and measuring its characteristics, while computational biology helps relate those measurements to biological processes. Artificial intelligence algorithms then analyse patterns in the data. Rather than treating every result as an isolated number, the software is intended to interpret measurements in the context of an individual’s previous results, potentially improving the detection of clinically meaningful trends.

However, the system is not designed to replace medical expertise. Blood results can be affected by factors including infection, medication, hydration, recent treatment and the quality of the sample. AI-generated outputs must therefore be evaluated against established laboratory methods and interpreted alongside a patient’s symptoms and clinical history. The technology’s current development programme includes further testing and evaluation in commercial deployment, as well as the collection of scientific evidence needed to determine how reliably it performs in different healthcare environments.

The device has achieved the UKCA regulatory mark, indicating that it meets relevant UK requirements for health, safety and environmental protection. This milestone allows the technology to progress towards wider use, but it does not by itself establish that the system can replace every laboratory test or make autonomous medical decisions. Algocyte is continuing to work through additional regulatory steps and clinical evaluation as it explores applications in routine monitoring and, potentially, predictive healthcare.

The possible impact extends beyond individual patients. Millions of blood tests are carried out in the United Kingdom each year to diagnose disease, monitor treatment and assess general health. Many require appointments, sample transport and laboratory processing, placing demands on clinical staff and healthcare infrastructure. A reliable point-of-care system could help redistribute some of this workload, allowing healthcare professionals to focus laboratory resources on complex analyses while routine measurements are collected closer to the patient.

The PROXIMA™ Mobile Health Station was officially launched at the Royal Society of Medicine in London on 29 June, following the achievement of its UKCA marking. The event brought together researchers, clinicians, industry partners and healthcare leaders to discuss the device’s future development, clinical validation and potential applications. Hector Zenil, Algocyte’s founder and chief executive and an associate professor in healthcare engineering at King’s College London, described the project as an example of how academic research in artificial intelligence, cell biology and medicine can be translated into technologies with potential social impact. If further testing confirms its accuracy and clinical value, the system could help transform blood monitoring from an episodic hospital procedure into a more continuous and personalised part of healthcare.

Subject of Research: Portable AI-enabled blood testing and remote health monitoring

Article Title: A Pocket-Sized AI Blood Analyzer Could Bring Continuous Health Monitoring Into the Home

References: King’s College London and Algocyte announcement concerning the PROXIMA™ Mobile Health Station and its UKCA marking

Keywords

Portable blood testing, artificial intelligence, home healthcare, remote monitoring, point-of-care diagnostics, chemotherapy monitoring, clozapine monitoring, bioengineering, digital health, King’s College London, Algocyte, PROXIMA Mobile Health Station

Optical biosensors have long been pivotal in scientific and medical fields due to their ability to detect molecules using light waves. These sensors function by probing biological samples, offering insights critical for personalized medicine, early disease diagnosis, and pollution monitoring. However, a persistent challenge has been to confine light waves to the nanometer scale—dimensions comparable to individual proteins or amino acids—to improve detection sensitivity. Conventional methods employ intricate nanophotonic structures that “squeeze” light at the surface of a chip, but these systems typically necessitate external lasers or light sources, resulting in complex and costly instrumentation unsuitable for rapid or point-of-care applications.

Turning to quantum mechanics provided the breakthrough. The team’s innovation rests on exploiting inelastic electron tunneling, a phenomenon where electrons, considered as waves rather than mere particles, have a finite probability of traversing an ultra-thin insulating barrier, simultaneously emitting photons—packets of light—in the process. Engineering a nanostructure that both composes part of the tunneling barrier and enhances photon emission probability was key to transforming this subtle quantum effect into a practical light source embedded directly within the sensor.

At the heart of the device’s architecture lies a meticulously designed nanoscale assembly comprising an aluminum oxide insulating layer and an ultrathin gold film. When electrons are driven through the aluminum oxide by applying a voltage, they occasionally tunnel across this barrier into the gold. This tunneling event transfers energy to collective electron oscillations within the gold—plasmons—which subsequently relax by emitting photons. Notably, the intensity and spectral characteristics of this photon emission shift in response to the interaction with biomolecules on the sensor’s surface, effectively translating biological information into an optical signal without the need for fluorescent labels or external lasers.

The sensor’s core innovation is its gold metasurface, fashioned as an arrayed mesh of nanoscale gold wires acting as optical nanoantennas. This metasurface serves dual purposes: it forms part of the quantum tunneling junction and simultaneously governs the spatial and spectral distribution of the emitted light. By concentrating light into nanometric volumes exactly where biomolecules can interact, these nanoantennas significantly amplify detection sensitivity and specificity, enabling the device to discern molecular phenomena at previously unreachable scales.

Despite the inherently low-probability nature of inelastic electron tunneling, the researchers ingeniously countered this by scaling the process over a macroscopic area. By integrating the quantum tunneling mechanism uniformly across a sizeable surface, the biosensor accumulates sufficient photon emission to generate meaningful signals, overcoming a fundamental limitation. This approach contrasts sharply with traditional single-point detection methods, exemplifying a promising blueprint for future quantum-enabled sensing platforms.

Performance evaluations of the biosensor demonstrated its ability to detect amino acids and polymers at concentrations in the picogram range—equivalent to one trillionth of a gram. Such sensitivity rivals or even exceeds that of current cutting-edge biosensors, underscoring the system’s potential for real-world applications. Furthermore, the detection is label-free and occurs in real time, a significant advantage for clinical diagnostics and environmental monitoring where speed and ease of use are paramount.

Fabrication leveraged EPFL’s state-of-the-art Center of MicroNanoTechnology facilities, ensuring that the sensor is not only highly functional but also scalable, compatible with established manufacturing techniques, and compact. The active sensing area encompasses less than a square millimeter, heralding the feasibility of integrating these biosensors into handheld devices for decentralized and rapid testing scenarios. Such portability could be transformative for healthcare delivery in resource-limited settings and for on-site detection of environmental pollutants.

This technology represents a synthesis of multiple advanced scientific concepts. The interplay between quantum electron behavior, plasmonic resonances of nanostructured metals, and precise nanofabrication has yielded a new class of biosensors capable of merging light generation and detection into a single integrated chip. The seamless coalescence of these functions eliminates bulky optical setups and lowers barriers to widespread deployment.

Collaborations with leading institutions worldwide, including ETH Zurich, ICFO in Spain, and Yonsei University in Korea, attest to the global significance and multidisciplinary nature of this breakthrough. The findings were recently published in the prestigious journal Nature Photonics, an acknowledgment of both the scientific rigor and the high potential impact of the work.

Looking ahead, the quantum plasmonic biosensor platform opens numerous avenues for innovation. Beyond medical diagnostics and environmental sensing, the fundamental scientific insights could influence a broader array of fields such as quantum computing, nano-optics, and materials science. The concept of harnessing quantum tunneling for integrated light generation signals a paradigm shift in photonic device engineering.

In summary, this self-illuminating plasmonic biosensor stands as a pioneering example of how quantum mechanics can transcend theoretical curiosities, evolving into practical, scalable technologies with societal relevance. By embedding quantum light sources directly into chip-scale devices, the researchers have created a new frontier in biosensing technology—one that promises unprecedented sensitivity, compactness, and versatility across numerous domains.

Subject of Research: Quantum plasmonic biosensors utilizing inelastic electron tunneling for sensitive biomolecule detection
Article Title: Plasmonic biosensor enabled by resonant quantum tunnelling
News Publication Date: 26-Jun-2025
Web References: https://doi.org/10.1038/s41566-025-01708-y
References: Masharin et al., Nature Photonics, 2025
Image Credits: 2025 Ella Maru Studio/BIOS EPFL CC BY SA 4.0